Immunotherapy in Hepatocellular Carcinoma

doi:10.3390/books978-3-0365-6690-0

Download Url(s)

https://mdpi.com/books/pdfview/book/7115

Contributor(s)

Nishida, Naoshi (editor)

Kudo, Masatoshi (editor)

Language

English

Show full item record

Abstract

Based on this evidence, a deep understanding of the immunological status and biological targets modulating immunological microenvironments should be quite informative for the development of future immunotherapy in HCC. From this point of view, this Special Issue will highlight the current state of the art in the immunotherapy of HCC from both the basic and clinical perspectives, and outline future perspectives for improving therapies.

URI

https://directory.doabooks.org/handle/20.500.12854/100022

Keywords

cancer immunotherapy; TCGA; mutations; copy number variations; microRNAs; PD-1; PD-L1; hepatocellular carcinoma; predictive factors; immunotherapy; immune checkpoint inhibition; check-point inhibitors; liver disease; outcome; biomarkers; combination immunotherapy; immune-related adverse events (irAEs); hepatocellular carcinoma (HCC); alpha fetoprotein response; immune checkpoint inhibitor; unresectable hepatocellular carcinoma; a disintegrin and metalloprotease 9; nivolumab; natural killer; CTLA-4; combination therapy; PD-1 antibody; PD-L1 antibody; anti-VEGF inhibitor; molecular classification; immune phenotype; stem cell marker; oncogenic signal; β-catenin; genetic alteration; liver cancer; effectiveness; safety; HCC; molecular-targeted agent; TACE; tyrosine kinase inhibitor; CD14+ cells; programmed death 1 ligands; translational approaches; combination therapies; therapy resistance; predictive markers; tissue-resident memory CD8 T cells; immune checkpoint blockade